 |
14 Diseases |  |
0 Trials |
|
0 Trials |  |
37 News |  |
- | Journal: Nonopioid drugs for pain. (Pubmed Central) - Mar 3, 2022
No abstract available
- | ketorolac / Generic mfg., celecoxib oral / Generic mfg.
Journal: Comparison table: Some nonopioid analgesics for pain. (Pubmed Central) - Mar 3, 2022
No abstract available No abstract available
- | celecoxib oral / Generic mfg.
Journal: Effects of Food on Bioavailability of Analgesics; Resulting Dosage and Administration Recommendations. (Pubmed Central) - May 15, 2021
No abstract available Overall, because food effects could alter the onset and/or duration of pain relief, analgesic medication should be used as per labeled recommendations for proper pain management.
- ||||||| fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
Trial completion: FACT OA2: Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (clinicaltrials.gov) - Nov 19, 2020
P3, N=1650, Completed, Sponsor: Regeneron Pharmaceuticals
Overall, because food effects could alter the onset and/or duration of pain relief, analgesic medication should be used as per labeled recommendations for proper pain management. Active, not recruiting --> Completed
- | fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip (clinicaltrials.gov) - Nov 19, 2020
P2, N=23, Terminated, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed N=50 --> 23 | Trial completion date: Jun 2021 --> Aug 2020 | Enrolling by invitation --> Terminated | Trial primary completion date: Jun 2021 --> Aug 2020; Lack of enrollment
- ||||| fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
Enrollment closed: FACT OA2: Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (clinicaltrials.gov) - Jun 27, 2019
P3, N=1650, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=50 --> 23 | Trial completion date: Jun 2021 --> Aug 2020 | Enrolling by invitation --> Terminated | Trial primary completion date: Jun 2021 --> Aug 2020; Lack of enrollment Recruiting --> Active, not recruiting
- |||| fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
Trial completion date, Trial primary completion date: FACT OA2: Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (clinicaltrials.gov) - Jun 4, 2019
P3, N=1620, Recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Jun 2020 --> Jan 2021 | Trial primary completion date: Jul 2019 --> Jan 2020
- || fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
New P2 trial: Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip (clinicaltrials.gov) - May 13, 2019
P2, N=50, Enrolling by invitation, Sponsor: Regeneron Pharmaceuticals
- | fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
Enrollment change: FACT OA2: Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (clinicaltrials.gov) - Sep 6, 2018
P3, N=1620, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jun 2020 --> Jan 2021 | Trial primary completion date: Jul 2019 --> Jan 2020 N=2700 --> 1620
- |||||| fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
Enrollment open: FACT OA2: Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (clinicaltrials.gov) - Dec 6, 2017
P3, N=2700, Recruiting, Sponsor: Regeneron Pharmaceuticals
N=2700 --> 1620 Not yet recruiting --> Recruiting
- |||||||||| fasinumab (REGN475) / Teva, Mitsubishi Tanabe, Regeneron
New P3 trial: FACT OA2: Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (clinicaltrials.gov) - Oct 8, 2017
P3, N=2700, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- | Zorvolex (diclofenac) / Assertio
Trial completion, Surgery: Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age (clinicaltrials.gov) - Apr 27, 2016
P2a, N=30, Completed, Sponsor: Iroko Pharmaceuticals, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Zorvolex (diclofenac) / Assertio
Enrollment closed, Surgery: Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age (clinicaltrials.gov) - Mar 29, 2016
P2a, N=30, Active, not recruiting, Sponsor: Iroko Pharmaceuticals, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Zorvolex (diclofenac) / Assertio
Enrollment open, Surgery: Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age (clinicaltrials.gov) - May 23, 2015
P2a, N=30, Recruiting, Sponsor: Iroko Pharmaceuticals, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Zorvolex (diclofenac) / Assertio
New P2a trial, Surgery: Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age (clinicaltrials.gov) - Apr 23, 2015
P2a, N=30, Not yet recruiting, Sponsor: Iroko Pharmaceuticals, LLC
- ||||||| Zorvolex (diclofenac) / Assertio
Trial completion: Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain (clinicaltrials.gov) - Apr 7, 2014
P3, N=602, Completed, Sponsor: Iroko Pharmaceuticals, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Zorvolex (diclofenac) / Assertio
Trial completion: Study of Diclofenac Capsules to Treat Osteoarthritis Pain (clinicaltrials.gov) - Jan 28, 2013
P3, N=307, Completed, Sponsor: Iroko Pharmaceuticals, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Zorvolex (diclofenac) / Assertio
Trial completion: Study of Diclofenac Capsules to Treat Pain Following Bunionectomy (clinicaltrials.gov) - Jan 6, 2013
P3, N=428, Completed, Sponsor: Iroko Pharmaceuticals, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Zorvolex (diclofenac) / Assertio
New P3 trial: Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain (clinicaltrials.gov) - Jan 11, 2012
P3, N=600, Active, not recruiting, Sponsor: Iroko Pharmaceuticals, LLC
- |||||||||| Zorvolex (diclofenac) / Assertio
New P3 trial: Study of Diclofenac Capsules to Treat Pain Following Bunionectomy (clinicaltrials.gov) - Oct 27, 2011
P3, N=428, Completed, Sponsor: Iroko Pharmaceuticals, LLC
- |||||||||| Zorvolex (diclofenac) / Assertio
New P3 trial: Study of Diclofenac Capsules to Treat Osteoarthritis Pain (clinicaltrials.gov) - Oct 26, 2011
P3, N=307, Completed, Sponsor: Iroko Pharmaceuticals, LLC